Alexandra Gerlach, Associate Editor

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

A fatal pediatric measles case in Los Angeles highlights the urgent need for MMR vaccination to protect vulnerable children from severe complications.

Pharmacists play a crucial role in managing myelofibrosis, enhancing patient education, adherence, and financial navigation for optimal care.

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

Florida's Surgeon General's plan to eliminate school vaccine mandates raises concerns about measles outbreaks and declining vaccination rates.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.

HHS and Robert F. Kennedy Jr prepare to unveil a report linking Tylenol use in pregnancy to autism, despite inconsistent study findings.

Patritumab deruxtecan shows promising efficacy in HR+/HER2– metastatic breast cancer, meeting key trial end points and highlighting its potential for advanced treatment.

Experts discuss radon—the second leading cause of lung cancer.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the challenges of managing myelofibrosis, from its heterogeneity and symptom burden to limited curative options.

Health officials warn of rising Chagas disease cases in the US, linked to kissing bugs and the parasite Trypanosoma cruzi, urging public awareness.

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Zongertinib promises significant advancements in patient care.

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

Women using depot medroxyprogesterone acetate face a significantly higher risk of meningioma, especially with long-term use or starting after age 31.

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared with intravenous administration, enhancing patient outcomes.

Rilzabrutinib gained FDA approval as the first BTK inhibitor for chronic immune thrombocytopenia, offering new hope for patients with persistent symptoms.

Explore the impact of the Inflation Reduction Act on community oncology practices and discover how new legislation aims to protect patient access to care.

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.

Drug shortages challenge US health care, driven by systemic issues like low pricing and manufacturing concentration, impacting patient care and safety.

GLP-1 receptor agonists like semaglutide show promise in reducing obesity-related cancer risks, while highlighting the need for ongoing safety monitoring.

Pharmacists play crucial roles in opioid use disorder treatment.

The new data highlight how dietary changes could fuel Alzheimer- and dementia-related mechanisms.

A patient, who formerly had previously been treated with CAR therapy for multiple myeloma, achieved remission for both multiple myeloma and lymphoma.

The study results could help bolster metformin as a potentially attractive option for patients with HER2-positive breast cancer.

The "farm effect" is a term researchers use to describe the protective impact of growing up on traditional farms—especially around livestock, barns, and raw farm environments—on the development of allergies and asthma.

Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.

The AAP unveiled its 2025 immunization schedule, challenging CDC guidelines and emphasizing evidence-based vaccine recommendations for children's health.